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P<0.05 for all comparisons TAXUS vs Control except TLR in DM insulin group (p=0.32)
Conclusions. TLR was significantly improved in all diabetics, diabetics on oral meds and 
trended towards improvement in the insulin-requiring diabetic group. Significant benefits 
of the paclitaxel-eluting TAXUS stent for QCA parameters (binary restenosis and late 
loss) compared with control were demonstrated in all three diabetic groups, including 
those requiring insulin. The beneficial effect of the TAXUS stent seen in the overall study 
population is preserved in the high-risk diabetic groups.
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1059-6 The Multicenter Evaluation of the Everolimus-Eluting 
Stent for Inhibition of Neointimal Hyperplasia: Results 
of the Pooled FUTURE I and II Trials
Ricardo A. Costa, Alexandra J. Lansky, Roxana Mehran, Yoshihiro Tsuchiya, Ecaterina 
Cristea, Yeal Gilutz, Maria Coral, Manuela Negoita, Ramona Pop, Michael Rink, Ralf 
Muller, George Techen, Eberhard Grube, Cardiovascular Research Foundation, New 
York, NY, Heart Center, Siegburg, Germany
The single center first-in-man randomized FUTURE I trial, demonstrated safety and
effectiveness of the everolimus-eluting stent (EES) to inhibit neointimal proliferation in de
novo coronary lesions compared to the bare metal stent (BMS). The FUTURE II trial was
a larger multicenter randomized trial of the EES, with inclusion of more complex patients,
such as diabetics. We report the 6-month results of the FUTURE I + II trials. Methods
and Results: 106 patients with 107 de novo coronary lesions were randomized to EES
(n=48) vs. BMS (n=58). Baseline clinical and angiographic characteristics were similar in
both groups, with 16% diabetics and lesion length of 10.42±3.37mm. Final and 6-month
angiographic results are shown in the Table. Conclusions: Patients treated with the EES
in the FUTURE I and II trials, had a dramatic decrease in late loss both in-stent (85.9%)
and in-segment (66%) compared to the bare metal stent group at 6 months. Concor-
dantly, restenosis was also significantly reduced with EES both within the stent and the
treated segment.
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1059-7 Impact of Late Loss on Clinical, Angiographic and 
Intravascular Ultrasound Outcomes in the TAXUS IV 
Trial
Stephen Ellis, Jeffrey J. Popma, Neil Weissman, Mark Turco, Ronald Caputo, Patrick 
Bergin, Joel Greenberg, Albert Raizner, Joerg Koglin, Mary E. Russell, Gregg W. Stone, 
The TAXUS IV Investigators, Brigham and Women's Hospital, Boston, MA, Cleveland 
Clinic Foundation, Cleveland, OH
Background. The optimal amount of late loss for drug-eluting stents has yet to be deter-
mined, but theoretically should be a balance between positive and negative remodeling.
The relationship between angiographic late loss and target lesion revascularization
(TLR), binary restenosis, and neointimal volume has also not been studied with drug-
eluting stents.
Methods. TAXUS IV was a prospective, randomized, double-blind study in which 1,314
patients at 73 US sites were randomized to the polymer-based paclitaxel slow release
TAXUS Express stent (n=662) or bare metal Express stent (n=652).
Results. As shown in the table, the 9-month rates of TLR, angiographic restenosis, and
IVUS neointimal volume were markedly reduced with the TAXUS stent compared to con-
trol. 
Regression analysis showed that TLR and binary restenosis were correlated with late 
loss. At late loss levels of less than approximately 0.6 mm the likelihoods of TLR and 
binary restenosis were between 0% and 1%. TLR and binary restenosis occurred in 50% 
of patients when late loss was ~1.6 mm and ~1.2 respectively.
Conclusions. Angiographic late loss levels <0.6 mm are associated with a low likelihood 
of clinical TLR, angiographic restenosis, and neointimal obstruction. Late loss at 9 
months by baseline RVD, lesion length and other variables will be further explored.
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1059-8 Coronary Plaque Regression by Simvastatin Is 
Associated With Reduction in Vessel Volume: A Three-
Dimensional Intravascular Ultrasound Study
Lisette Okkels Jensen, Per Thayssen, Knud Erik Pedersen, Torben Haghfelt, Odense 
University Hospital, Odense, Denmark
Background: In the early stage of the coronary atherosclerotic plaques, pathophysiolog-
ical studies have demonstrated that the vessel wall may remodel and accumulate plaque
material without causing morphologically detectable changes in lumen diameter. The aim
of the study was to investigate the effect of lipid-lowering by simvastatin on coronary ath-
erosclerotic plaques as well as changes in the volumes of plaque, lumen and vessel.
Methods: In 40 male patients with hypercholesterolemia and a non significant coronary
artery lesion 3D IVUS during ECG-triggered pullback was performed at baseline, after 3
months on a lipid lowering diet and after another12 months on diet plus simvastatin 40
mg/day. All segments contained at least one side branch used for the correct matching of
the site of measurement at follow-up.
Results: Mean length of the analysed atherosclerotic segments was 5.9 ± 3.3 mm.
Twenty-three left anterior descending coronary artery segments, 6 circumflex segment
and 11 right coronary artery segments were analysed. Mean minimal lumen diameter
was 2.6 ± 0.6 mm, maximum plaque burden was 62.1 ± 13.6 % and mean diameter of
reference segments were 3.5 ± 0.6 mm. After 12 months on simvastatin the reductions in
total cholesterol of 31.0% (6.1 ± 0.8 vs. 4.2 ± 0.7, p<0.001) and LDL cholesterol of 42.6%
(4.0 ± 0.8 vs. 2.2 ± 0.6, p<0.001) were significant.
After 12 months on simvastatin a significant reduction in plaque volume of 6.9%
(p<0.001) and vessel volume of 3.6% (p<0.001) were observed without any concomitant
change in lumen volume. There was a significant linear correlation between the percent-
age change in volume for plaque and vessel (r=0.652, p<0.001), lumen and vessel
(r=0.737, p<0.001), while there was no correlation between plaque and lumen (r=0.027,
p=0.869) after 12 months simvastatin therapy.
Conclusion: Lipid-lowering therapy with simvastatin for 12 months is associated with a
significant plaque regression in coronary arteries measured as reduction in plaque and
vessel volumes without any concomitant change in lumen volume. An explanation for this
may be that remodeling takes place in the vessel wall only.
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1059-9 Platelet P-Selectin and Plasma Levels of Circulating 
Cytokines in Young Patients With Mild Arterial 
Hypertension
Christian Stumpf, Jelena Jukic, Atilla Yilmaz, Stefan John, Dorette Raaz, Roland E. 
Schmieder, Werner G. Daniel, Christoph D. Garlichs, University of Erlangen, Erlangen, 
Germany, University of Erlangen, Erlangen, Germany
The role of inflammatory mechanisms for the development of vascular damage in athero-
sclerosis (AS) has been increasingly acknowledged during recent years. In this setting
animal models have revealed the important role of platelet P-selectin on progression of
AS. Although these observations have stimulated research on the role of vascular inflam-
mation in patients with arterial hypertension (AH), the overall contribution of inflammation
in AH, one of the leading cardiovascular risk factors, is far from being clear. Therefore,
the present pilot study was designed to examine the role of platelet P-selectin and vari-
ous inflammatory mediators in an early stage of AH in young patients without signs of tar-
get organ damage. 
15 patients with mild AH (33.8+7.3 years, systolic blood pressure [SBP] 143.8+10.5
mmHg, diastolic blood pressure [DBP] 88.2+11.1 mmHg, mean arterial pressure [MAP]
106.6+10.4 mmHg) and 15 healthy normotensive controls (31.7+10.6 years) were exam-
ined. Blood was drawn from a peripheral vein. Platelet P-selectin was analysed by flow
cytometry. MCP-1, hsCRP, interleukin (IL)-6, TNFα, and IL-10 levels were measured via
EIA. 
AH patients showed significantly enhanced expression of platelet P-selectin (17.2+5.4 vs
10.6+4.2 mean fluorescence intensity [MFI], p<0.001). P-selectin expression positively
correlated with MAP (r=0.58, p<0.001). Furthermore AH patients had significantly
enhanced plasma levels of hsCRP (2.7+3.8 vs 0.6+0.9 mg/L, p<0.01), IL-6 (1.4+0.7 vs
0.6+0.3 pg/mL, p<0.001), TNFα (2.8+0.7 vs. 2.4+0.4 pg/mL, p<0.05) and MCP-1
(291.3+100.7 vs 214.3+8.3 pg/mL, p<0.05). IL-6 levels positively correlated with hsCRP
levels (r=0.80, p<0.001) and MAP (r=0.68, p<0.01).
This pilot study demonstrates that in an early state of AH inflammatory mechanisms are
already activated. Beside proinflammatory cytokines, platelets seem to play an important
role in mediating inflammation in the progression of AH. It is possible that these mecha-
nisms play a pathogenic role in mediating target organ injury. However further investiga-
tions have to clarify the role of an early anti-inflammatory therapy in patients with mild to
moderate AH to alleviate hypertensive target organ damage.
Noon
1059-10 Antibodies to Infectious Pathogen Are Associated With 
Hypertension
Jianhui Zhu, Arshed Quyyumi, Daniel Canos, Julian Halcox, Stephen Epstein, 
Washington Hospital Center, Washington, DC
Background: Infection has been implicated as contributing to the pathogenesis of athero-
sclerosis. Given the recognized relationship between hypertension (HTN) and athero-
sclerosis, this study determined whether antibodies to infectious pathogens are
associated with HTN, and whether this association is, in part, through infection-induced
inflammation. Methods: We evaluated 415 patients (62% men, mean age 57 years) for
Quantitative Coronary Angiography
Variable (Number of Lesions) EES (N=49) BMS (N=58) P-value
Reference Diameter, mm 3.01±0.42 2.97±0.51 0.6
Final MLD, mm 2.98±0.38 2.88±0.38 0.2
Acute Gain, mm 1.90±0.43 1.83±0.44 0.5
FU Stent MLD, mm 2.86±0.41 2.04±0.68 <0.0001
FU Segment MLD, mm 2.32±0.52 1.77±0.62 <0.0001
Stent Late Loss, mm 0.12±0.25 0.85±0.53 <0.0001
Segment Late Loss, mm 0.17±0.36 0.50±0.51 0.0005
Stent Restenosis, % 0.0% 17.0% 0.006
Segment Restenosis, % 4.3% 27.7% 0.002
TLR (%) Binary restenosis
(%, in-stent)
% in-stent net volume 
obstruction
Late loss (mm)
TAXUS 3.0 5.5 12.2 0.39 ±0.50
Control 11.3 24.4 29.4 0.92 ±0.58
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the presence of HTN (n=217, 52%) if the arterial pressure was >140/90 mm Hg and/or
they were being treated for HTN, and tested serum IgG antibodies to cytomegalovirus,
hepatitis A virus, Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus type
1 and type 2, as well as C-reactive protein (CRP) levels. Results: The prevalence of anti-
bodies to hepatitis A virus or Helicobacter pylori, but not to others, was higher in the HTN
than the non-HTN patients. These associations were significant even after adjustment for
traditional risk factors. Adjusted OR with 95%CL was 1.59 (1.05-2.40) for hepatitis A virus
and 1.75 (1.15-2.68) for Helicobacter pylori infection. In addition, increasing number of
seropositivities (pathogen burden) was significantly associated with increasing HTN risk.
The prevalence of HTN was 58% in the high pathogen burden group (>4 positive antibod-
ies) compared with 45% in the low burden group (P<0.01). The pathogen burden
remained a significant predictor of HTN after multivariate analysis (adjusted OR 1.60 with
95% CL 1.05-2.42). Interestingly, we found that elevated CRP levels (>0.5mg/dL) were
also associated with HTN (adjusted OR 1.80 with 95% CL 1.12-2.87), and that elevated
CRP levels combined with individual infections and pathogen burden increased the risk
of HTN: adjusted OR with 95% CL was 3.09 (1.56-6.12) for hepatitis A virus, 3.68 (1.83-
7.40) for Helicobacter pylori, and 3.15 (1.56-6.37) for pathogen burden. Conclusion: Our
data suggest that infection plays a role in the development of HTN, and elevated CRP
levels can increase the risk posed by infection in HTN.
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1059-11 Venous Endothelium Dysfunction Is Also Presented in 
Hypertensive Patients
Marcelo C. Rubira, Fernanda Marciano Consolim-Colombo, Rodrigo Dm Plentz, Eneida 
Rejane Rabelo, Juan Carlos Yugar-Toledo, Heitor Moreno Junior, Eduardo Moacir 
Krieger, Maria Claudia Irigoyen, Heart Institute, University of São Paulo, Medical School, 
Brazil, São Paulo, Brazil, Federal University of São Paulo, Brazil, São Paulo, Brazil
Background: Endothelium dysfunction has been demonstrated in the arteries of hyper-
tensive patients. Although veins and arteries produce nitric oxide, it is unknown if the
formers are also impaired in the arterial hypertension. The aims of this study were: 1) To
evaluate whether or not the hypertensive patients exhibit venous endothelium dysfunc-
tion; 2) To determine the relationship between endothelium dependent and independent
vasodilation responses in venous and arterial systems in these subjects.
Methods: Sixteen patients with mild hypertension (SBP 145.8 +/- 8.8 mm Hg and DBP
98.3 +/- 4.8 mm Hg), out of medication and without other risk factor, and fifteen matched
normotensive volunteers had the venous and arterial endothelial function evaluated,
respectively, by the dorsal hand vein (DHV) and high resolution ultrasound (flow medi-
ated dilation - FMD) techniques.
Results: The maximal dilation response (Emax), produced by acetylcholine (ACH) was
consistently reproducible, allowing evaluating the venous endothelium dependent
response. Hypertensive group had a marked reduction of Emax to ACh (54,9+/-10,8%)
when compared to normotensive controls (Emax= was 85,2+/-27,0%). The flow mediated
dilation responses were reduced in the hypertensive subjects compared to their controls
(6.6+/1.3 versus 12.4+/-1.4 %, respectively). The responses to nitric oxide donors were
similar in both groups tested by the DHV and FMD methods. By the analysis of the mea-
surement method comparison data (Bland & Altman), the responses both techniques
agreed in normotensive and hypertensive subjects.
Conclusion: Hypertensive patients had an attenuated endothelial-dependent response,
indicating that the endothelium dysfunction observed in arteries is also present in the
venous system.
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1059-12 Sustained Upregulation of Inflammatory Cytokine and 
Its Receptor Genes Associated With Proteinase 
Activation in Abdominal Aortic Aneurysm: Results 
From Combined Study With cDNA Array and Real-Time 
Reverse Transcriptase Polymerase Chain Reaction 
Methods
Takeo Higashikata, Masakazu Yamagishi, Hiroaki Sasaki, Kenji Minatoya, Hitoshi Ogino, 
Hatsue Ishibashi-Ueda, Aiji Sakamoto, Hitonobu Tomoike, National Cardiovascular 
Center Research Institute, Suita, Japan
Background: In the development of aortic aneurym, inflammatory process plays a piv-
otal role in the vessel tissue degradation. Under these conditions, cytokines are known to
serve as an essential mediator of inflammation, contributing to degenerating local tissue
associated with or without aneurysm formation probably through the activation of protein-
ases. However, few data exist regarding which cytokines are important for proteinase
activation associated aneurysm formation. Therefore, we analyzed gene expression lev-
els of cytokines, their receptors and proteinases such as matrix metalloproteinase
(MMPs) in abdominal aortic aneurysm (AAA) by cDNA array and real-time RT-PCR meth-
ods.
Methods and Results: Aortic samples from the maximally dilated and non-dilated (con-
trol) regions were obtained from 22 patients with graft replacement surgery for AAA. The
32P-labeled cDNA probe mixture synthesized from 5 microgram total RNA with gene-
specific primers was hybridized with 388 cytokine-related cDNA array. For 4 pairs of AAA
and control, the signal intensities for each target cDNA normalized to GAPDH were com-
pared. Overt upregulation in AAA was observed for Interleukin (IL)-8 and its receptor
such as CXCR-2, which were further confirmed by real-time RT-PCR method. We also
determine gene expression level of MMP-1, 3, and 9. The expression levels for the IL-8
and CXCR-2 genes were significantly upregulated in AAA compared with control as fol-
lowed: IL-8, 0.53 ± 0.16 Versus 0.11 ± 0.04 (p<0.01); CXCR-2, 2.04 ± 0.75 Versus 0.29 ±
0.10 (p<0.01). Under these conditions, there was significant upregulation of MMP-1 (4.48
± 2.01 Versus 0.26 ± 0.12, p<0.01) and MMP-3 (5.01 ± 0.97 Versus 1.89 ± 1.00, p<0.05)
genes.
Conclusion: Sustained upregulation of IL-8, a CXC-chemokine, and its receptor, CXCR-
2, was observed in the AAA associated with overexpression of MMPs, suggesting that
inflammatory process with proteinase activation contributes to the development of AAA.
This pathway may be an alternative gene or drug target for the treatment of AAA.
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1059-13 Detection and Propagation of Calcified Nanostructures 
From Human Aneurysms
John C. Lieske, Vivek Kumar, Gerard Farell-Baril, Shihui Yu, Jon E. Charlesworth, Ewa 
Rzewuska-Lech, Peter LaBreche, Sandra R. Severson, Virginia M. Miller, Mayo Clinic 
Rochester, Rochester, MN
Background: Mechanisms leading to vascular calcification remain incompletely under-
stood. Nanometer-sized, mineralized structures recognized by a commercially available
monoclonal antibody (8D10, Nanobac OY) are present in calcified human aneurysms.
These structures were not detected by TUNEL staining, suggesting they were not apop-
totic bodies. The 8D10 antibody is directed against nanobacteria, a controversial, slow-
growing, and calcifying microorganism. Therefore, experiments were designed to deter-
mine whether structures from aneurysms are viable, nano-sized organisms.
Methods: Aneurysms (n=3) collected as surgical waste were decalcified, sterile filtered
(0.22 µm), and cultured in DMEM containing gamma-irradiated calf serum.
Results: In 2 of 3 cultures micron-sized particles visible by light microscopy increased in
number over 4-6 weeks. The negative culture came from an aneurysm without stainable
nanoparticles. With transmission electron microscopy (EM), cultured particles showed an
inner core surrounded by a shell of calcium phosphate (documented via energy disper-
sive microanalysis). After dissolution of the shell with EDTA, spherical structures of 50-
100 nm were seen by scanning EM. These cultured particles incorporated [3H]uridine at
a rate 2.3 times greater than control cultures of DMEM containing serum and inorganic
hydroxyapatite (HA) crystals (P<0.01). Therefore, these nanostructures appear to syn-
thesize RNA. Particles cultured from aneurysms also stained with the 8D10 antibody, and
SDS-PAGE of extracted proteins revealed multiple distinct bands, including one (Mr 47
kDa) recognized by the 8D10 antibody. The pattern of proteins extracted from inorganic
HA crystals incubated with DMEM and calf serum did not contain the 47-kDa band rec-
ognized by the 8D10 antibody.
Conclusion: In conclusion, these results suggest that viable nano-sized organisms are
present within calcified human arterial tissue. A cause and effect relationship between
the presence of these organisms and development of arterial calcification remains to be
determined.
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1059-14 C825T Polymorphism of the G-Protein Beta(3) Subunit 
Gene and Atrial Fibrillation: Association of the TT 
Genotype With a Reduced Risk for Atrial Fibrillation
Juergen Schreieck, Stefan Dostal, Nicolas von Beckerath, Annette Wacker, Michelle 
Flory, Sonja Weyerbrock, Sebastian Schmieder, Werner Koch, Claus Schmitt, Deutsches 
Herzzentrum München and 1. Med. Klinik, TU München, Munich, Germany
Background: A polymorphism consisting of a C825T substitution in the G-protein beta(3)
subunit gene (GNB3) has been associated with enhanced signal transduction via het-
erotrimeric G-proteins. Furthermore, association between enhanced human atrial inward
rectifier potassium currents and the TT genotype, but not the CT genotype has been
shown. Therefore, we investigated a possible impact of the GNB3 C825T polymorphism
on atrial fibrillation by genotyping patients with atrial fibrillation and a control cohort of
patients without atrial tachyarrhythmias. Methods: 291 consecutive patients admitted to
our center with symptomatic paroxysmal or persistent AF (mean age 58±10 years) and
292 control patients (59±11 years) were genotyped for the C825T polymorphism.
Patients with coronary heart disease, valvular heart disease or cardiomyopathy were
excluded from the study in order to avoid the influence of disease-related atrial remodel-
ing. Control subjects were 292 consecutive patients admitted to our center in which coro-
nary artery disease was excluded by coronary angiography. The control group had a
similar incidence of cardiovascular risk factors (hypertension, hypercholesterolemia,
body mass index) as the group with atrial fibrillation. Results: The prevalence of the
GNB3 TT genotype was significantly lower in patients with atrial fibrillation (5.8%) than in
the control group (12.0%); however, no significant differences in the frequencies of the
CT and CC genotypes were found. TT genotype was associated with a 51% decrease in
the unadjusted risk (OR: 0.49, 95% CI=0.28-0.85, P=0.01) and a 54% decrease in the
adjusted risk (OR from a multivariant model: 0.46, 95% CI=0.24-0.87, P=0.02) for the
occurrence of atrial fibrillation. Sinus cycle length, P wave duration, PQ interval and rate-
corrected QT interval (QTc) during sinus rhythm were not influenced by the genotype.
Conclusion: The present study suggests an association between the GNB3 TT genotype
and a reduced risk for the occurrence of atrial fibrillation.
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1059-15 Early Administration of Clopidogrel Is Safe After Off- 
Pump Coronary Artery Bypass Surgery
Michael E. Halkos, William A. Cooper, Rebecca Petersen, Omar M. Lattouf, John D. 
Puskas, Joseph M. Craver, Robert A. Guyton, Emory University School of Medicine, 
Atlanta, GA
Background: Patients who undergo off-pump coronary artery bypass (OPCAB) may be
hypercoagulable with an increased risk of early graft thrombosis due to the lack of plate-
let dysfunction that accompanies “on-pump” coronary artery bypass. Clopidogrel, a
